Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.
about
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsVirus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeuticMolecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage.Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoproteinEquine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infectionAccurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model.N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus.Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins.The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.Partial HIV C2V3 envelope sequence analysis reveals association of coreceptor tropism, envelope glycosylation and viral genotypic variability among Kenyan patients on HAART.Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virusAntibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIV(SF33A) molecular clones.Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same siteIncreased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory workerStabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle.HIV N-linked glycosylation site analyzer and its further usage in anchored alignment.
P2860
Q28217208-E57D5F28-00A6-4454-B276-72F738D089E5Q30368471-2FFE96E4-0021-422A-8939-582843EB1A48Q33737723-5EC35B61-F118-4345-818A-43F3CB9818DCQ33843345-CB58036B-258A-4874-A260-CA26229B8AE7Q33951963-A9C0C33B-E82C-4D21-93D3-718EEA5A8443Q34069846-F32D4031-7DA8-415E-8D99-9F830DE87CD3Q34338411-C1DEF490-E6CF-40B8-9739-95ED0AE38EDEQ34347265-77B4A36B-9668-40BC-9653-44DE94EC0BBBQ34349343-B03BD60A-8F55-42A1-9DC8-4DDE38404E4FQ34464860-FBE15728-19AD-4B6F-BF55-2E009506E142Q34465007-2B79A530-D433-4B8F-8007-025134F5BAA8Q34555891-62746319-FC96-4D5B-98BB-E7733BA178F3Q35020604-1B83FC7F-375E-4E83-B0B1-C5D8402E2BA6Q35173635-FEAC3086-5D36-46EB-A443-1EB656B9CFA4Q35635163-E22BD308-7362-4DC4-BB57-5B4E3DDC1843Q36337888-E0FBC660-DB66-454F-86BD-3B3167F9C2B6Q36565090-0AD41301-2BDA-4D96-AB39-21B2CB264E89Q36953913-A8351485-D20C-4A19-AA5A-921B5B4C6884Q37010292-CFF78DF2-3BE8-4FA0-B5E2-0648A1E64299Q37410770-03A4155E-551C-4F30-903E-725ABC69327CQ37415987-21D61334-846B-4FA1-8248-59FA73BC0DF7Q37547702-730EA0B0-A6E9-495D-8C68-042FF2F5CFBBQ37642937-985F3922-7A0C-4D60-BD85-826BF9CE77B8Q37682968-FC75B1AC-85BA-4EFA-B3B1-5EDEBBAF3CADQ39305772-93EA1EB8-EB68-49D2-8C14-2C34185B6DE3Q39682485-41DAC26F-BC05-4E99-85DD-E08EBB5CCE21Q39698363-2AC4BD2C-90ED-430E-9F91-A58D382C394BQ39699375-5909FC7E-344B-4788-895A-D3C38F325F82Q40883803-A7E8F69B-8B55-4962-BA01-E86AF5BA503EQ42052623-2DBC3280-A3DB-423E-8D6F-6F853E5FC6C3Q43116285-F2F3C433-8789-4175-A8D5-E7EB0F7C599D
P2860
Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Envelope glycoprotein determin ...... derived by passage in monkeys.
@ast
Envelope glycoprotein determin ...... derived by passage in monkeys.
@en
type
label
Envelope glycoprotein determin ...... derived by passage in monkeys.
@ast
Envelope glycoprotein determin ...... derived by passage in monkeys.
@en
prefLabel
Envelope glycoprotein determin ...... derived by passage in monkeys.
@ast
Envelope glycoprotein determin ...... derived by passage in monkeys.
@en
P2860
P1433
P1476
Envelope glycoprotein determin ...... derived by passage in monkeys.
@en
P2860
P304
P356
10.1128/JVI.75.9.4208-4218.2001
P577
2001-05-01T00:00:00Z